Search Antibody Database

Found 1 matching record:

Displaying record number 233

Download this epitope record as JSON.

MAb ID	1D9D5 (1D9)
HXB2 Location	Tat(2-21) DNA(5834..5893)	Tat Epitope Map
Author Location	Tat
Epitope	EPVDPRLEWKHPGSQPKTA	Epitope Alignment
Ab Type	N-term
Neutralizing
Species (Isotype)	mouse(IgG1)
Patient
Immunogen	vaccine
Keywords	antibody interactions, binding affinity

Vaccine Details

Notes

Showing 5 of 5 notes.

• 1d9: Database comment: the database contains distinct antibodies named 1D9 and 1d9. Also, Ab 1D9D5 is referred to as 1D9 by Theisen2006.
• 1D9: This mouse anti-Tat antibody is referred to as both 1D9D5 and 1D9 in this paper. This Ab was used as a positive control in the binding activity assay. It was shown, however, that the 1D9 bound slightly weaker to Tat then the PTD-scFvtat1 fusion complex. Theisen2006 (antibody interactions, binding affinity)
• 1D9D5: Similarity level of the 1D9D5 binding site pentapeptide EWKHP to the host proteome was low, with the low-similarity 5-mer occurring in the host proteome 0 times, indicating that this peptide can be used to elicit Abs for active/passive immunotherapy with low risk of cross-reaction with the host proteome. Kanduc2008
• 1D9D5: Exogenously delivered Tat can efficiently transactivate an HIV-LTR-CAT construct in HeLa cells in the presence of 1D9D5, suggesting when considered with the results of Mhashilkar1995, that free Tat and not Ab bound is taken up by cells Valvatne1996. Mhashilkar1995,Valvatne1996
• 1D9D5: Single chain antibodies, intrabodies, were engineered that can be stably expressed in the cytoplasm of mammalian cells -- co-expression of an N-term intrabody can inhibit transactivation of an HIV LTR-CAT construct and block import into nucleus, but intrabody specific for exon 2 did not inhibit activity. Mhashilkar1995

References

Showing 4 of 4 references.

Kanduc2008 Darja Kanduc, Rosario Serpico, Alberta Lucchese, and Yehuda Shoenfeld. Correlating Low-Similarity Peptide Sequences and HIV B-Cell Epitopes. Autoimmun. Rev., 7(4):291-296, Feb 2008. PubMed ID: 18295732. Show all entries for this paper.

Mhashilkar1995 A. M. Mhashilkar, J. Bagley, S. Y. Chen, A. M. Szilvay, D. G. Helland, and W. A. Marasco. Inhibition of HIV-1 Tat-Mediated LTR Transactivation and HIV-1 Infection by Anti-Tat Single Chain Intrabodies. EMBO J., 14:1542-1551, 1995. Anti-Tat intrabodies specific for the N-terminal activation domain of Tat, block Tat-mediated transactivation of the HIV-1 LTR and intracellular trafficking of Tat in mammalian cells. Thus single chain intrabodies can effectively target molecules in the cytoplasm and nuclear compartments of eukaryotic cells and anti-Tat intrabodies may be useful for gene therapy of HIV-1 infection and AIDS. PubMed ID: 7537216. Show all entries for this paper.

Theisen2006 Dietmar M. Theisen, Carola Pongratz, Katja Wiegmann, Francisco Rivero, Oleg Krut, and Martin Krönke. Targeting of HIV-1 Tat Traffic and Function by Transduction-Competent Single Chain Antibodies. Vaccine, 24(16):3127-3136, 12 Apr 2006. PubMed ID: 16497417. Show all entries for this paper.

Valvatne1996 H. Valvatne, A. M. Szilvay, and D. E. Helland. A Monoclonal Antibody Defines a Novel HIV Type 1 Tat Domain Involved in Trans-Cellular Trans-Activation. AIDS Res. Hum. Retroviruses, 12:611-619, 1996. CAT and beta-galactosidase assays, and immunofluorescence analysis were used to study the cellular uptake of the HIV-1 Tat protein. A MAb binding to the basic domain and the RGD sequence inhibits trans- activation by exogenous Tat. The inhibition of the cellular uptake of Tat by an anti-Tat monoclonal antibody and by the serum components implies specific binding of Tat to the cell membrane. PubMed ID: 8743086. Show all entries for this paper.